Wockhardt Limited DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

About Contact Details

At the heart of our efforts and investment in this complex, futuristic field is the customer, for whom we develop cost-effective biopharmaceuticals to treat life-threatening ailments. Our pioneering efforts in biotechnology have led to the launch of three successful products in the Indian market - Glaritus (long-acting 24-hr insulin analog), Wosulin (recombinant insulin), Wepox (erythropoietin) and Biovac-B (hepatitis B vacci...

At the heart of our efforts and investment in this complex, futuristic field is the customer, for whom we develop cost-effective biopharmaceuticals to treat life-threatening ailments. Our pioneering efforts in biotechnology have led to the launch of three successful products in the Indian market - Glaritus (long-acting 24-hr insulin analog), Wosulin (recombinant insulin), Wepox (erythropoietin) and Biovac-B (hepatitis B vaccine). Glaritus - Wockhartd was the first Company in the world after the innovator to launch this breakthrough product. A recombinant long-acting human insulin analog, glargine (branded Glaritus) is formulated on the world-class E.Coli platform technology. Its upstream and downstream processes match international cGMP norms and Wockhardt became a name to reckon with in the biotechnology space – moving from simple biologicals to complex biologicals.